Zentalis Pharmaceuticals (ZNTL) PT Raised to $50 at Morgan Stanley
Tweet
Share
E-mailGet Alerts ZNTL Hot Sheet
Price: $2.52 -3.45%
Rating Summary:
9 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 15 | New: 50
Rating Summary:
9 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 15 | New: 50
Join SI Premium – FREE
Morgan Stanley analyst Matthew Harrison raised the price target on Zentalis Pharmaceuticals (NASDAQ: ZNTL) to $50.00 (from $49.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Wells Fargo Assumes Zentalis Pharmaceuticals (ZNTL) at Equal Weight
- Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Macquarie Upgrades Merdeka Copper Gold Tbk PT (MDKA:IJ) to Outperform
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
